Afrezza®, a dry-powder formulation of recombinant human regular insulin, was recently approved by the US Food and Drug Administration.[1] Afrezza is indicated for use in adults ≥ 18 years of age with type 1 or type 2 diabetes mellitus (T1DM or T2DM); however, in those with T1DM, Afrezza must be used in combination with long-acting insulin.

Read more